Genetic Technologies (GENE) Stock Price, News & Analysis

Company Overview

Genetic Technologies (NASDAQ: GENE) is a biotechnology company focused on the development and commercialization of advanced genetic risk assessment tools for complex diseases. The company leverages proprietary algorithms and large-scale genomic data to deliver polygenic risk scores that help individuals and healthcare providers assess susceptibility to conditions such as breast cancer, cardiovascular disease and metabolic disorders. Genetic Technologies operates as both a direct provider of testing services and a licensor of its underlying technology to third-party laboratories and research institutions.

Central to Genetic Technologies’ product portfolio is TruRisk®, a clinically validated breast cancer risk test that combines multiple genetic variants with traditional risk factors to refine risk estimations. The company also offers personal genetic assessment panels covering diseases including rheumatoid arthritis, osteoporosis and type 2 diabetes. These products are designed to integrate with electronic health records and support precision prevention strategies by identifying high-risk individuals for early intervention and tailored screening protocols.

Genetic Technologies serves a global market, with commercial operations in the United States, Europe, Australia and parts of Asia. The company collaborates with academic institutions, health systems and specialty clinics to advance research on polygenic risk models and expand the adoption of genomics-based preventive care. Through strategic partnerships and licensing agreements, Genetic Technologies aims to embed its risk scoring solutions into wellness programs and payer-driven value-based care initiatives.

Founded in 1994 and headquartered in Melbourne, Australia, Genetic Technologies has evolved from a pioneer in single-gene testing to a leader in polygenic risk assessment. The company listed on the Australian Securities Exchange before completing a U.S. listing on the NASDAQ to support its international growth. The senior management team is led by Chief Executive Officer Bill Faraone and supported by a board of directors with extensive experience in biotechnology, diagnostics and corporate governance. Genetic Technologies continues to invest in research and development to refine its risk models and address emerging opportunities in precision health.

Key Stats

• Today's Range: $0.77 to $0.77
• 50-Day Range: $0.77 to $0.77
• 52-Week Range: $0.67 to $3.77
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $3.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GENE Stock Analysis - Frequently Asked Questions

When did Genetic Technologies' stock split?

Genetic Technologies's stock reverse split on Monday, December 4th 2023.The 1-5 reverse split was announced on Monday, December 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genetic Technologies investors own include Netflix (NFLX), Plug Power (PLUG), Meta Platforms (META), OPKO Health (OPK), Nokia (NOK), Novavax (NVAX) and iBio (IBIO).

Company Calendar

• Today: 7/16/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GENE
• CIK: 1166272
• Web: www.gtgcorporate.com
• Phone: (138) 412-7000
• Fax: 011-61-3-8412-7040
• Employees: 50
• Year Founded: 1989

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 0.88
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $7.66 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 3.06

Miscellaneous

• Outstanding Shares: 4,407,000
• Free Float: 4,534,000
• Market Cap: $3.37 million
• Optionable: Optionable
• Beta: 1.12